CLASSIC HODGKIN LYMPHOMA

This study tests a personalized approach for people with early-stage Hodgkin lymphoma. Doctors use PET scans to decide if standard chemotherapy alone is enough or if adding immunotherapy drugs can improve results. The goal is to boost survival while limiting unnecessary treatment…

This early-phase study tests whether adding an oral drug (CC-486) to the immunotherapy nivolumab can help people with Hodgkin lymphoma whose cancer did not respond to PD-1 therapy. CC-486 may make cancer cells more visible to the immune system, potentially restoring nivolumab's e…

This study tests a combination of two drugs, nivolumab and brentuximab vedotin, in people aged 60 or older (or younger people who cannot take standard chemotherapy) with untreated Hodgkin lymphoma. The goal is to see how well this drug pair works in shrinking or eliminating the c…

This study tests whether giving two immunotherapy drugs—nivolumab and brentuximab vedotin—after a stem cell transplant can help keep high-risk Hodgkin lymphoma from coming back. The trial includes 62 patients whose lymphoma had returned or did not respond to earlier treatments. T…

This large phase 3 study compares two immunotherapy drugs (nivolumab or brentuximab vedotin) given with standard chemotherapy for people aged 12 and older with newly diagnosed, advanced-stage classical Hodgkin lymphoma. The goal is to see which combination better delays the cance…

This study tests whether adding brentuximab vedotin (a drug that delivers cancer-killing substances directly to lymphoma cells) to standard chemotherapy works better than chemo alone for children and young adults with high-risk Hodgkin lymphoma. About 600 participants with stage …